Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab-Reference-Cited by-同舟云学术

Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Published:2020-02 Issue: Volume:101 Page:104525
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Matsuo Mioko,Yasumatsu Ryuji,Masuda Muneyuki^ORCID,Toh Satoshi,Wakasaki Takahiro,Hashimoto Kazuki,Taura Masahiko,Uchi Ryutaro,Nakagawa Takashi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference24 articles.

1. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

2. Pseudoprogression and hyperprogression after checkpoint blockade;Wang;Int Immunopharmacol,2018

3. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N Engl J Med,2017

5. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis;Ricciuti;J Cancer Res Clin Oncol,2019

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter to the Editor: “Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma”;Oral Oncology;2024-09

2. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation;Cancers;2024-07-12

3. Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma;Cancer Medicine;2024-06

4. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG);European Archives of Oto-Rhino-Laryngology;2024-05-25

5. The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland;Clinical Oncology;2024-05